Rapid Drug
Development Platform
Advanced Gene & Cell
Therapy Platform
Yielding Cures for Serious Diseases
VIEW PIPELINE
HIV Cure Program
HIV+ Individuals Become Immune to HIV
No More Daily Antiretrovirals
Clinical Trial Forecast 2nd Half 2020
LEARN MORE
Cancer Cure Program
Stimulating the Natural Immune System
(Gamma Delta T Cells) to Safely Remove
Solid Tumors
Human Trial Forecast for 2021
LEARN MORE
Phenylketonuria
Cure Program
A One Time Treatment For PKU
That Lasts a Lifetime
Forecast for Human Trials 2021
LEARN MORE
FDA APPROVES AMERICAN GENE TECHNOLOGIES (AGT) TO MOVE FORWARD WITH PHASE 1 CLINICAL TRIAL OF HIV CURE PROGRAM
Fulfilling Our Vision
October of 2016, AGT had a meeting with the FDA to propose a new approach for treating HIV-infected individuals that would render them durably immune to HIV, eliminating the pain and side-effects of current lifelong antiretroviral regimens. AGT's goal is to restore normal quality of life without the fear of progression to AIDS, transmission of HIV to others, or reinfection.
October of 2019, AGT submitted an Investigational New Drug (IND) application to the FDA seeking approval to begin a human trial of AGT’s unique immuno-regulatory approach. AGT believes we may be able to restore effective HIV immunity to HIV infected individuals. The submission of the IND is a critical step forward in verifying our approach.
Watch clips from AGT's red carpet event celebrating its IND submission to the FDA.
Who We Are
American Gene Technologies International Inc. (AGT) is a private biotechnology company pursuing cures and treatments for Infectious diseases, cancers and monogenic disorders.
AGT's programs are designed to:
What We Do
For over a decade, AGT has developed, tested and banked thousands of lentiviral vectors that can be adapted to the specific needs of new target diseases. AGT has developed gene therapy for diseases using this rapid gene delivery platform
Gene Therapies
AGT’s platform allows it to pursue exciting clinical “cures” in large and orphan indications and complex diseases. The company has developed individual, intellectual property protected gene therapeutics that are breakthroughs in medicine.
GENE THERAPY
HIV/AIDS
Immunotherapy for HIV disease with gene modified T cells
IMMUNO-ONCOLOGY
Liver Cancer
Activates innate T cell immunity capable of killing all tumor cells with its vector used in immuno-oncology
GENE THERAPY
Phenylketonuria (PKU)
Treats PKU by bringing a functional gene into cells that express a dysfunctional gene due to mutation
Pipeline
American Gene Technologies™ (AGT) is building a rich product pipeline based on its lentiviral vector platform. Our three lead programs are well into the laboratory phase and scheduled to move into the clinic over the coming months.
Our Executive Team
American Gene Technologies™ (AGT) is building a rich product pipeline based on its lentiviral vector platform. Our three leading therapeutics are well into the laboratory phase and scheduled to move into the clinical phase over the course of the next 6-18 months. AGT is in the process of testing and commercializing genetic medicines that will cure or halt the progression of several major diseases.
Jeff Galvin
CEO and
Founder
Jeff earned his BA degree in Economics from Harvard in 1981. He has more than 30 years of business and entrepreneurial experience including founder or executive positions at a variety of Silicon Valley startups. Several of his companies were taken public and/or sold to public companies.
C. David Pauza, PhD
Chief Science
Officer
David has 35 years of experience in HIV, immunology, virology, and cancer biology, and has held faculty positions and at University of Wisconsin and University of Maryland medical schools. Prior to joining AGT, David was Adjunct Professor of Medicine at the University of Maryland Medical School in Baltimore.
C. Neil Lyons, CPA
Chief Financial Officer &
Executive Vice President
Neil has more than 30 years of experience in finance, strategy, raising capital, SEC compliance, and corporate governance in both public and private companies, with over 10 years of that leading finance for publicly-traded, clinical-stage biotechnology companies.
Kelly Huang, PhD
Director, Preclinical
Product Development
Kelly brings more than 10 years of experience in biopharma drug development, and has lead teams to support the development of drugs targeting diverse therapeutic areas including infectious disease, autoimmunity, and oncology.
AGT's Core Objectives
Is the cure for cancer right around the corner?…
Advances in gene technologies and the resulting cures are accelerating exponentially while costs are coming down. If you were in Silicon Valley for the last 35 years, you’d recognize parallels to many previous high-tech “explosions” such as microcomputers, software and the Internet. “Moore’s Law” now applies to drug development and the next big startup could be up in a garage near you! Forget zeroes and ones… A-C-G-T is the new growth area of programming and real-world solutions. Viva la revolution!
